Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Carole Diane Mitnick, Sc.D.

Title
Institution
Department
Address
Phone
Fax

Mentoring
Detection of hypertension as risk factor in chronic kidney disease and access to medical care in Quezalguaque, Leon, Nicaragua
International, 06/16/10 - 08/08/10
Spanish and Service Learning Program in Santiago, Chile 2005
International, 06/19/05 - 08/12/05
Chile Spanish Language and Service Learning Program 2005
International, 06/20/05 - 08/12/05
An assessment of the efficacy, access-to-care, and sustainability of a recently established national cataract elimination program in Peru
International, 06/18/09 - 08/10/09
Service Learning Program in Santiago, Chile - summer 2005
Spanish, 06/19/05 - 08/12/05

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U01AI091429 (MITNICK, CAROLE D) Aug 20, 2011 - Jul 31, 2017
    NIH
    Randomized Trial of High-Dose Rifampin in Patients with New Smear-Positive TB
    Role: Co-Principal Investigator
  2. R34AI073369 (MITNICK, CAROLE D) Jul 15, 2007 - Jun 30, 2010
    NIH
    Randomized Trial of High-Dose Rifampin in Patients with New, Smear-Positive TB
    Role: Principal Investigator
  3. K01AI065836 (MITNICK, CAROLE D) Sep 15, 2006 - Aug 31, 2010
    NIH
    Clinical Outcomes Research in MDR-TB
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. McKenna L, Frick M, Angami K, Dubula V, Furin J, Harrington M, Hausler H, Heitkamp P, Herrera R, Lynch S, Mitnick CD, Moses GK, Ndjeka N, Nyang'wa BT, Palazuelos L, Ulysse P, Pai M. The 1/4/6x24 campaign to cure tuberculosis quickly. Nat Med. 2023 Jan 10. PMID: 36627438.
    Citations:    Fields:    
  2. Tzelios C, Contreras C, Istenes B, Astupillo A, Lecca L, Ramos K, Ramos L, Roca K, Galea JT, Tovar M, Mitnick CD, Peinado J. Using digital chatbots to close gaps in healthcare access during the COVID-19 pandemic. Public Health Action. 2022 Dec 21; 12(4):180-185. PMID: 36561900; PMCID: PMC9716819.
    Citations:    
  3. Rodriguez CA, Lodi S, Horsburgh CR, Bastard M, Hewison C, Huerga H, Khan M, Khan PY, Khan U, Oyewusi L, Padayachee S, Mitnick CD, Franke MF. Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion. PLoS One. 2022; 17(11):e0276457. PMID: 36355658; PMCID: PMC9648724.
    Citations:    Fields:    Translation:HumansCells
  4. Huerga H, Khan U, Bastard M, Mitnick CD, Lachenal N, Khan PY, Seung KJ, Melikyan N, Ahmed S, Rich ML, Varaine F, Osso E, Rashitov M, Salahuddin N, Salia G, Sánchez E, Serobyan A, Rafi Siddiqui M, Grium Tefera D, Vetushko D, Yeghiazaryan L, Holtzman D, Islam S, Kumsa A, Jacques Leblanc G, Leonovich O, Mamsa S, Manzur-Ul-Alam M, Myint Z, Padayachee S, Franke MF, Hewison C. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs. Clin Infect Dis. 2022 10 12; 75(8):1307-1314. PMID: 35243494; PMCID: PMC9555840.
    Citations:    Fields:    
  5. Hewison C, Khan U, Bastard M, Lachenal N, Coutisson S, Osso E, Ahmed S, Khan P, Franke MF, Rich ML, Varaine F, Melikyan N, Seung KJ, Adenov M, Adnan S, Danielyan N, Islam S, Janmohamed A, Karakozian H, Kamene Kimenye M, Kirakosyan O, Kholikulov B, Krisnanda A, Kumsa A, Leblanc G, Lecca L, Nkuebe M, Mamsa S, Padayachee S, Thit P, Mitnick CD, Huerga H. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort. Clin Infect Dis. 2022 09 29; 75(6):1006-1013. PMID: 35028659; PMCID: PMC9522425.
    Citations:    Fields:    
  6. Jhaveri TA, Fung C, LaHood AN, Lindeborg A, Zeng C, Rahman R, Bain PA, Velásquez GE, Mitnick CD. Clinical Outcomes of Individuals with COVID-19 and Tuberculosis during the Pre-Vaccination Period of the Pandemic: A Systematic Review. J Clin Med. 2022 Sep 26; 11(19). PMID: 36233523; PMCID: PMC9570663.
    Citations:    
  7. Lindeborg MM, Jung DH, Chan DK, Mitnick CD. Prevention and management of hearing loss in patients receiving ototoxic medications. Bull World Health Organ. 2022 Dec 01; 100(12):789-796A. PMID: 36466201; PMCID: PMC9706352.
    Citations:    Fields:    Translation:Humans
  8. Schwalb A, Cachay R, Wright A, Phillips PPJ, Kaur P, Diacon AH, Ugarte-Gil C, Mitnick CD, Sterling TR, Gotuzzo E, Horsburgh CR. Factors associated with screening failure and study withdrawal in multidrug-resistant TB. Int J Tuberc Lung Dis. 2022 09 01; 26(9):820-825. PMID: 35996282.
    Citations:    Fields:    Translation:HumansCellsCTClinical Trials
  9. LaHood A, Rahman R, McKenna L, Frick M, Mitnick CD. Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different. PLoS One. 2022; 17(7):e0271102. PMID: 35877601; PMCID: PMC9312388.
    Citations:    Fields:    Translation:HumansCells
  10. Calderón RI, Jhaveri TA, Tovar MA, Palomino JS, Barreda NN, Sanabria OM, Peinado J, Ramirez C, Llanos Zavalaga LF, Valderrama G, Franke MF, Mitnick CD, Lecca L, Velásquez GE. Diagnostic Performance Assessment of Saliva RT-PCR and Nasopharyngeal Antigen for the Detection of SARS-CoV-2 in Peru. Microbiol Spectr. 2022 08 31; 10(4):e0086122. PMID: 35867471; PMCID: PMC9430815.
    Citations:    Fields:    
  11. Padovany MM, Patterson RH, Bowder AN, O'Brien E, Alkire BC, Katz AM, Mitnick CD, Lu C. Impact of out-of-pocket expenses for surgical care on households in rural Haiti: a mixed-methods study. BMJ Open. 2022 05 24; 12(5):e061731. PMID: 35613787; PMCID: PMC9125749.
    Citations:    Fields:    Translation:Humans
  12. Seung KJ, Franke MF, Hewison C, Huerga H, Khan U, Mitnick CD. Corrigendum to 'High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients' [J Hepatol 72 (2020) 1028-1029]. J Hepatol. 2022 Aug; 77(2):583. PMID: 35581037.
    Citations:    Fields:    
  13. Mohr-Holland E, Daniels J, Reuter A, Rodriguez CA, Mitnick C, Kock Y, Cox V, Furin J, Cox H. Early mortality during rifampicin-resistant TB treatment. Int J Tuberc Lung Dis. 2022 Feb 01; 26(2):150-157. PMID: 35086627; PMCID: PMC8802559.
    Citations:    Fields:    Translation:HumansCells
  14. Tovar M, Peinado J, Palomino S, Llanos F, Ramírez C, Valderrama G, Calderón RI, Williams RB, Velásquez GE, Mitnick CD, Franke MF, Lecca L. Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies Among Market and City Bus Depot Workers in Lima, Peru. Clin Infect Dis. 2022 01 29; 74(2):343-346. PMID: 33881476; PMCID: PMC8083218.
    Citations:    Fields:    Translation:HumansCells
  15. Khan PY, Franke MF, Hewison C, Seung KJ, Huerga H, Atwood S, Ahmed S, Khan M, Sultana T, Manzur-Ul-Alam M, Vo LNQ, Lecca L, Yae K, Kozhabekov S, Tamirat M, Gelin A, Vilbrun SC, Kikvidze M, Faqirzai J, Kadyrov A, Skrahina A, Mesic A, Avagyan N, Bastard M, Rich ML, Khan U, Mitnick CD. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings. Eur Respir J. 2022 01; 59(1). PMID: 34140298.
    Citations: 1     Fields:    Translation:Humans
  16. Tierney DB, Orvis E, Nathavitharana RR, Hurwitz S, Tintaya K, Vargas D, Segura P, de la Gala S, Lecca L, Mitnick CD, Nardell EA. FAST tuberculosis transmission control strategy speeds the start of tuberculosis treatment at a general hospital in Lima, Peru. Infect Control Hosp Epidemiol. 2022 10; 43(10):1459-1465. PMID: 34612182; PMCID: PMC8983787.
    Citations:    Fields:    
  17. Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, Chang E, Cloez S, Coit JM, Cox V, de Jong BC, Delifer C, Do JM, Tozzi DDS, Ducher V, Ferlazzo G, Gouillou M, Khan A, Khan U, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moschioni M, O'Brien K, Okunbor O, Oyewusi L, Panda S, Patil SB, Phillips PPJ, Pichon L, Rupasinghe P, Rich ML, Saluhuddin N, Seung KJ, Tamirat M, Trippa L, Cellamare M, Velásquez GE, Wasserman S, Zimetbaum PJ, Varaine F, Mitnick CD. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021 Sep 25; 22(1):651. PMID: 34563240.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  18. Mitnick CD, Furin JJ, Hewison C. The Reductionist Conundrum of an "Updated" Definition of Extensively Drug-Resistant Tuberculosis. Am J Respir Crit Care Med. 2021 09 15; 204(6):629-631. PMID: 34375572; PMCID: PMC8521709.
    Citations:    Fields:    Translation:Humans
  19. Asfaw MT, Holtzman DL, Kwan GF, Oyewusi LT, Mitnick CD, Seung KJ. INCIDENCE OF HIGH GRADE QTCF PROLONGATION AND ITS MANAGEMENT AMONG PATIENTS UNDERGOING TREATMENT FOR DRUG RESISTANT TUBERCULOSIS (DR-TB): CASE SERIES. Afr J Infect Dis. 2021; 15(2 Suppl):38-41. PMID: 34595385; PMCID: PMC8457348.
    Citations:    
  20. Rodriguez CA, Brooks MB, Aibana O, Mitnick CD, Franke MF. Sputum culture conversion definitions and analytic practices for multidrug-resistant TB. Int J Tuberc Lung Dis. 2021 07 01; 25(7):596-598. PMID: 34183109.
    Citations:    Fields:    Translation:HumansCells
  21. Nyang'wa BT, LaHood AN, Mitnick CD, Guglielmetti L. TB research requires strong protections, innovation, and increased funding in response to COVID-19. Trials. 2021 05 29; 22(1):371. PMID: 34051826; PMCID: PMC8164060.
    Citations:    Fields:    Translation:HumansCells
  22. Franke MF, Khan P, Hewison C, Khan U, Huerga H, Seung KJ, Rich ML, Zarli K, Samieva N, Oyewusi L, Nair P, Mudassar M, Melikyan N, Lenggogeni P, Lecca L, Kumsa A, Khan M, Islam S, Hussein K, Docteur W, Chumburidze N, Berikova E, Atshemyan H, Atwood S, Alam M, Ahmed S, Bastard M, Mitnick CD. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study. Am J Respir Crit Care Med. 2021 01 01; 203(1):111-119. PMID: 32706644; PMCID: PMC7781121.
    Citations: 9     Fields:    Translation:Humans
  23. Franke MF, Mitnick CD. Time for a change: considering regimen changes in analyses of observational drug-resistant TB treatment cohort data. Int J Tuberc Lung Dis. 2020 11 01; 24(11):1151-1155. PMID: 33172522.
    Citations:    Fields:    Translation:Humans
  24. Rodriguez CA, Sy KTL, Mitnick CD, Franke MF. Time-Dependent Confounding in Tuberculosis Treatment Outcome Analyses: A Review of a Source of Bias. Am J Respir Crit Care Med. 2020 11 01; 202(9):1311-1314. PMID: 32551891.
    Citations: 1     Fields:    Translation:Humans
  25. Brooks MB, Mitnick CD, Manjourides J. Comparison of censoring assumptions to reduce bias in tuberculosis treatment cohort analyses. PLoS One. 2020; 15(10):e0240297. PMID: 33075072; PMCID: PMC7571697.
    Citations: 1     Fields:    Translation:Humans
  26. Lachenal N, Hewison C, Mitnick C, Lomtadze N, Coutisson S, Osso E, Ahmed S, Leblanc G, Islam S, Atshemyan H, Nair P, Kholikulov B, Aiylchiev S, Zarli K, Adnan S, Krisnanda A, Padayachee S, Stambekova A, Sahabutdinova Y, de Guadalupe S, Moreno P, Kumsa A, Reshid A, Makaka J, Abebe S, Melikyan N, Seung KJ, Khan U, Khan P, Huerga H, Rich M, Varaine F. Setting up pharmacovigilance based on available endTB Project data for bedaquiline. Int J Tuberc Lung Dis. 2020 10 01; 24(10):1087-1094. PMID: 33126944.
    Citations:    Fields:    Translation:Humans
  27. Seung KJ, Khan U, Varaine F, Ahmed S, Bastard M, Cloez S, Damtew D, Franke MF, Herboczek K, Huerga H, Islam S, Karakozian H, Khachatryan N, Kliesckova J, Khan AJ, Khan M, Khan P, Kotrikadze T, Lachenal N, Lecca L, Lenggogeni P, Maretbayeva S, Melikyan N, Mesic A, Mitnick CD, Mofolo M, Perrin C, Richard M, Tassew YM, Telnov A, Vilbrun SC, Wanjala S, Rich ML, Hewison C. Introducing new and repurposed TB drugs: the endTB experience. Int J Tuberc Lung Dis. 2020 10 01; 24(10):1081-1086. PMID: 33126943.
    Citations:    Fields:    Translation:Humans
  28. Seung KJ, Khan P, Franke MF, Ahmed S, Aiylchiev S, Alam M, Putri FA, Bastard M, Docteur W, Gottlieb G, Hewison C, Islam S, Khachatryan N, Kotrikadze T, Khan U, Kumsa A, Lecca L, Tassew YM, Melikyan N, Naing YY, Oyewusi L, Rich M, Wanjala S, Yedilbayev A, Huerga H, Mitnick CD. Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis. Clin Infect Dis. 2020 07 11; 71(2):415-418. PMID: 31676905.
    Citations: 3     Fields:    Translation:HumansCells
  29. Lindeborg MM, Shakya P, Pradhan B, Rai SK, Gurung KB, Niroula S, Rayamajhi B, Chaudhary H, Gaire B, Mahato N, Rana L, Rokaya P, Shrestha N, Shrestha R, Tamang J, Joshi HD, Gaha P, Khorja DK, Nakarmi KK, Mitnick CD, Rai SM, Shaye DA. A task-shifted speech therapy program for cleft palate patients in rural Nepal: Evaluating impact and associated healthcare barriers. Int J Pediatr Otorhinolaryngol. 2020 Jul; 134:110026. PMID: 32272376.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  30. Campbell JR, Falzon D, Mirzayev F, Jaramillo E, Migliori GB, Mitnick CD, Ndjeka N, Menzies D. Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis. Emerg Infect Dis. 2020 03; 26(3). PMID: 31922953.
    Citations: 4     Fields:    Translation:HumansCells
  31. Seung KJ, Franke MF, Hewison C, Huerga H, Khan U, Mitnick CD. High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients. J Hepatol. 2020 05; 72(5):1028-1029. PMID: 32147086.
    Citations: 3     Fields:    Translation:Humans
  32. Lindeborg MM, Shakya P, Pradhan B, Rai SK, Gurung KB, Niroula S, Rayamajhi B, Chaudhary H, Gaire B, Mahato N, Rana L, Rokaya P, Shrestha N, Shrestha R, Tamang J, Joshi HD, Gaha P, Khorja DK, Mitnick CD, Rai SM, Shaye DA. Nepali Linguistic Validation of the Velopharyngeal Insufficiency Effects on Life Outcomes Instrument: VELO-Nepali. Cleft Palate Craniofac J. 2020 08; 57(8):967-974. PMID: 32054301.
    Citations: 1     Fields:    Translation:Humans
  33. Quispe N, Asencios L, Obregon C, Velásquez GE, Mitnick CD, Lindeborg M, Jave H, Solari L. The fourth national anti-tuberculosis drug resistance survey in Peru. Int J Tuberc Lung Dis. 2020 02 01; 24(2):207-213. PMID: 32127106.
    Citations: 3     Fields:    Translation:HumansCells
  34. Mukherjee J, Lindeborg MM, Wijayaratne S, Mitnick C, Farmer PE, Satti H. Global Cash Flows for Sustainable Development: A Case Study of Accountability and Health Systems Strengthening in Lesotho. J Health Care Poor Underserved. 2020; 31(1):56-74. PMID: 32037317.
    Citations: 1     Fields:    Translation:Humans
  35. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL, Duarte R, Fregonese F, Horsburgh CR, Ahmad Khan F, Kheir F, Lan Z, Lardizabal A, Lauzardo M, Mangan JM, Marks SM, McKenna L, Menzies D, Mitnick CD, Nilsen DM, Parvez F, Peloquin CA, Raftery A, Schaaf HS, Shah NS, Starke JR, Wilson JW, Wortham JM, Chorba T, Seaworth B. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019 11 15; 200(10):e93-e142. PMID: 31729908; PMCID: PMC6857485.
    Citations: 85     Fields:    Translation:Humans
  36. Lu C, Palazuelos D, Luan Y, Sachs SE, Mitnick CD, Rhatigan J, Perry HB. Development assistance for community health workers in 114 low- and middle-income countries, 2007-2017. Bull World Health Organ. 2020 Jan 01; 98(1):30-39. PMID: 31902960; PMCID: PMC6933433.
    Citations: 13     Fields:    Translation:Humans
  37. Becerra MC, Huang CC, Lecca L, Bayona J, Contreras C, Calderon R, Yataco R, Galea J, Zhang Z, Atwood S, Cohen T, Mitnick CD, Farmer P, Murray M. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ. 2019 10 24; 367:l5894. PMID: 31649017; PMCID: PMC6812583.
    Citations: 17     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
  38. Law S, Daftary A, Mitnick CD, Dheda K, Menzies D. Disrupting a cycle of mistrust: A constructivist grounded theory study on patient-provider trust in TB care. Soc Sci Med. 2019 11; 240:112578. PMID: 31585376.
    Citations: 8     Fields:    Translation:Humans
  39. Rodriguez CA, Mitnick CD, Franke MF. Value of observational data for multidrug-resistant tuberculosis. Lancet Infect Dis. 2019 09; 19(9):930-931. PMID: 31478514.
    Citations: 1     Fields:    Translation:Humans
  40. Khan U, Huerga H, Khan AJ, Mitnick CD, Hewison C, Varaine F, Bastard M, Rich M, Franke MF, Atwood S, Khan PY, Seung KJ. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens. BMC Infect Dis. 2019 Aug 20; 19(1):733. PMID: 31429722; PMCID: PMC6701145.
    Citations: 7     Fields:    Translation:Humans
  41. Franke MF, Rodriguez CA, Mitnick CD. Causal inference in tuberculosis treatment studies: bias considerations and data needs. Int J Tuberc Lung Dis. 2019 08 01; 23(8):960-961. PMID: 31533889.
    Citations: 1     Fields:    Translation:Humans
  42. Velásquez GE, Brooks MB, Coit JM, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Lecca L, Davies GR, Mitnick CD. Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis. Am J Respir Crit Care Med. 2019 05 01; 199(9):1167-1168. PMID: 30645140; PMCID: PMC6515881.
    Citations:    Fields:    Translation:Humans
  43. Phillips PPJ, Mitnick CD, Neaton JD, Nahid P, Lienhardt C, Nunn AJ. Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape. PLoS Med. 2019 03; 16(3):e1002767. PMID: 30901331.
    Citations: 9     Fields:    Translation:Humans
  44. Mitnick CD, Yuen CM. Tuberculosis active case-finding: more than just finding cases. Lancet Infect Dis. 2019 05; 19(5):456-457. PMID: 30910430.
    Citations:    Fields:    Translation:Humans
  45. Rodriguez CA, Brooks MB, Guglielmetti L, Hewison C, Jachym MF, Lessem E, Varaine F, Mitnick CD. Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study. Public Health Action. 2019 Mar 21; 9(1):32-41. PMID: 30963040; PMCID: PMC6436488.
    Citations:    
  46. Byrne AL, Marais BJ, Mitnick CD, Garden FL, Lecca L, Contreras C, Yauri Y, Garcia F, Marks GB. Asthma and atopy prevalence are not reduced among former tuberculosis patients compared with controls in Lima, Peru. BMC Pulm Med. 2019 Feb 13; 19(1):40. PMID: 30760258; PMCID: PMC6373156.
    Citations: 2     Fields:    Translation:Humans
  47. van Leth F, Brinkmann F, Cirillo DM, Dheda K, Duarte R, Guglielmetti L, Kuksa L, Lange C, Mitnick C, Skrahina A, Zaman K, Bothamley G. The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation. Eur Respir J. 2019 01; 53(1). PMID: 30606765.
    Citations: 1     Fields:    Translation:Humans
  48. Brooks MB, Keshavjee S, Gelmanova I, Zemlyanaya NA, Mitnick CD, Manjourides J. Use of predicted vital status to improve survival analysis of multidrug-resistant tuberculosis cohorts. BMC Med Res Methodol. 2018 12 11; 18(1):166. PMID: 30537944; PMCID: PMC6290510.
    Citations: 3     Fields:    Translation:Humans
  49. Horsburgh CR, Mitnick CD, Lange C. Walter Werner Holland, 1929-2018. Int J Tuberc Lung Dis. 2018 Dec 01; 22(12):121-122. PMID: 30606332.
    Citations:    
  50. Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Kaur P, Horsburgh CR. Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. Antimicrob Agents Chemother. 2018 10; 62(10). PMID: 30012767; PMCID: PMC6153781.
    Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
  51. Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018 09 08; 392(10150):821-834. PMID: 30215381; PMCID: PMC6463280.
    Citations: 162     Fields:    Translation:Humans
  52. Velásquez GE, Brooks MB, Coit JM, Pertinez H, Vargas Vásquez D, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Tierney DB, Seung KJ, Lecca L, Davies GR, Mitnick CD. Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 09 01; 198(5):657-666. PMID: 29954183; PMCID: PMC6118011.
    Citations: 27     Fields:    Translation:HumansCellsCTClinical Trials
  53. Velásquez GE, Davies GR, Mitnick CD. Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis. Int J Tuberc Lung Dis. 2018 05 01; 22(5):473-474. PMID: 29663947; PMCID: PMC5940349.
    Citations:    Fields:    Translation:Humans
  54. Lange C, van Leth F, Mitnick CD, Dheda K, Günther G. Time to revise WHO-recommended definitions of MDR-TB treatment outcomes. Lancet Respir Med. 2018 04; 6(4):246-248. PMID: 29595505.
    Citations: 1     Fields:    Translation:Humans
  55. McAnaw S, Rodriguez CA, Muller A, Mitnick C, Horsburgh CR. Has compassionate use ever sunk a drug? Int J Tuberc Lung Dis. 2018 02 01; 22(2):119-120. PMID: 29506605.
    Citations: 1     Fields:    Translation:Humans
  56. Byrne AL, Marais BJ, Mitnick CD, Garden FL, Lecca L, Contreras C, Yauri Y, Garcia F, Marks GB. Feasibility and yield of screening for non-communicable diseases among treated tuberculosis patients in Peru. Int J Tuberc Lung Dis. 2018 01 01; 22(1):86-92. PMID: 29297431.
    Citations: 6     Fields:    Translation:HumansPHPublic Health
  57. Varaine F, Guglielmetti L, Mitnick CD. Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. Am J Respir Crit Care Med. 2017 12 01; 196(11):1490-1491. PMID: 28715258.
    Citations:    Fields:    Translation:HumansCells
  58. Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. Trials. 2017 Nov 25; 18(1):563. PMID: 29178937.
    Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
  59. Farhat MR, Jacobson KR, Franke MF, Kaur D, Murray M, Mitnick CD. Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study. Clin Infect Dis. 2017 Oct 15; 65(8):1364-1370. PMID: 29017248; PMCID: PMC5850426.
    Citations: 5     Fields:    Translation:HumansCells
  60. Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Garavito ES, Vasquez DV, Mitnick CD, Davies G. Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis". Antimicrob Agents Chemother. 2017 09; 61(9). PMID: 28839086; PMCID: PMC5571311.
    Citations: 1     Fields:    
  61. Calderón RI, Velásquez GE, Becerra MC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Kritski AL, Murray MB, Mitnick CD. Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru. Int J Tuberc Lung Dis. 2017 08 01; 21(8):894-901. PMID: 28786798; PMCID: PMC5555119.
    Citations: 5     Fields:    Translation:Humans
  62. Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick CD, Davies G. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. Antimicrob Agents Chemother. 2017 08; 61(8). PMID: 28559269; PMCID: PMC5527578.
    Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
  63. Guglielmetti L, Varaine F, Huerga H, Bonnet M, Rich ML, Mitnick CD. Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance. Eur Respir J. 2017 07; 50(1). PMID: 28729476.
    Citations: 3     Fields:    Translation:HumansCells
  64. Byrne AL, Marais BJ, Mitnick CD, Garden FL, Lecca L, Contreras C, Yauri Y, Garcia F, Marks GB. Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis. ERJ Open Res. 2017 Jul; 3(3). PMID: 28717643; PMCID: PMC5507160.
    Citations: 7     
  65. Velásquez GE, Calderon RI, Mitnick CD, Becerra MC, Huang CC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Murray MB. Erratum for Velásquez et al., Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2017 Mar; 61(3). PMID: 28232308; PMCID: PMC5328511.
    Citations:    Fields:    
  66. Nourzad S, Jenkins HE, Milstein M, Mitnick CD. Estimating the global burden of multidrug-resistant tuberculosis among prevalent cases of tuberculosis. Int J Tuberc Lung Dis. 2017 01 01; 21(1):6-11. PMID: 28157458; PMCID: PMC5381649.
    Citations: 1     Fields:    Translation:Humans
  67. Kendall EA, Cohen T, Mitnick CD, Dowdy DW. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. Int J Infect Dis. 2017 Mar; 56:185-189. PMID: 28007660; PMCID: PMC5576040.
    Citations: 5     Fields:    Translation:HumansCells
  68. Cellamare M, Milstein M, Ventz S, Baudin E, Trippa L, Mitnick CD. Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial. Int J Tuberc Lung Dis. 2016 12 01; 20(12):8-12. PMID: 28240566.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  69. Milstein M, Brzezinski A, Varaine F, Mitnick CD. (Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016 12 01; 20(12):18-23. PMID: 28240568.
    Citations: 1     Fields:    Translation:Humans
  70. Horsburgh CR, Rusen ID, Mitnick CD. Optimizing MDR-TB clinical trials: insights from the first global MDR-TB Clinical Trials Landscape Meeting. Int J Tuberc Lung Dis. 2016 12 01; 20(12):1-3. PMID: 28240564.
    Citations:    Fields:    Translation:Humans
  71. Guglielmetti L, Le Dû D, Fréchet-Jachym M, Mitnick C. Preventing Acquired Resistance to Bedaquiline and Delamanid in Multidrug-Resistant Tuberculosis Treatment Requires Optimal Management. Am J Respir Crit Care Med. 2016 11 01; 194(9):1170-1171. PMID: 27797614.
    Citations: 1     Fields:    Translation:Humans
  72. Tierney DB, Milstein MB, Manjourides J, Furin JJ, Mitnick CD. Treatment Outcomes for Adolescents With Multidrug-Resistant Tuberculosis in Lima, Peru. Glob Pediatr Health. 2016; 3:2333794X16674382. PMID: 27826599; PMCID: PMC5084611.
    Citations: 5     
  73. Velásquez GE, Calderon RI, Mitnick CD, Becerra MC, Huang CC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Murray MB. Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2016 11; 60(11):6766-6773. PMID: 27600032; PMCID: PMC5075084.
    Citations: 8     Fields:    Translation:HumansCells
  74. Varaine F, Guglielmetti L, Huerga H, Bonnet M, Kiria N, Sitienei JK, Rich M, Mitnick CD. Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations. Am J Respir Crit Care Med. 2016 10 15; 194(8):1028-1029. PMID: 27739887.
    Citations: 5     Fields:    Translation:Humans
  75. Cellamare M, Ventz S, Baudin E, Mitnick CD, Trippa L. A Bayesian response-adaptive trial in tuberculosis: The endTB trial. Clin Trials. 2017 Feb; 14(1):17-28. PMID: 27559021.
    Citations: 11     Fields:    Translation:Humans
  76. Mitnick CD, White RA, Lu C, Rodriguez CA, Bayona J, Becerra MC, Burgos M, Centis R, Cohen T, Cox H, D'Ambrosio L, Danilovitz M, Falzon D, Gelmanova IY, Gler MT, Grinsdale JA, Holtz TH, Keshavjee S, Leimane V, Menzies D, Migliori GB, Milstein MB, Mishustin SP, Pagano M, Quelapio MI, Shean K, Shin SS, Tolman AW, van der Walt ML, Van Deun A, Viiklepp P. Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. Eur Respir J. 2016 10; 48(4):1160-1170. PMID: 27587552; PMCID: PMC5045442.
    Citations: 14     Fields:    Translation:HumansCells
  77. Milstein M, Lecca L, Peloquin C, Mitchison D, Seung K, Pagano M, Coleman D, Osso E, Coit J, Vargas Vasquez DE, Sanchez Garavito E, Calderon R, Contreras C, Davies G, Mitnick CD. Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. BMC Infect Dis. 2016 08 27; 16(1):453. PMID: 27567500; PMCID: PMC5002098.
    Citations: 12     Fields:    Translation:Humans
  78. Mitnick CD, Rodriguez CA, Hatton ML, Brigden G, Cobelens F, Grobusch MP, Horsburgh R, Lange C, Lienhardt C, Oren E, Podewils LJ, Seaworth B, van den Hof S, Daley CL, Gebhard AC, Wares F. Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda. PLoS One. 2016; 11(5):e0155968. PMID: 27223622; PMCID: PMC4880345.
    Citations: 9     Fields:    Translation:Humans
  79. Fox GJ, Benedetti A, Mitnick CD, Pai M, Menzies D. Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. PLoS One. 2016; 11(3):e0151724. PMID: 27022741.
    Citations: 1     Fields:    Translation:Humans
  80. Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P. Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. Int J Tuberc Lung Dis. 2016 Mar; 20(3):290-4. PMID: 27046707.
    Citations: 4     Fields:    Translation:HumansCells
  81. Parr JB, Rich ML, Keshavjee S, Franke MF, Mitnick CD, Bayona J, Becerra MC. Presumptive treatment of multidrug-resistant tuberculosis in household contacts. Int J Tuberc Lung Dis. 2016 Mar; 20(3):370-5. PMID: 27046719.
    Citations: 1     Fields:    Translation:HumansCells
  82. Mitnick C, van den Hof S. Using existing data to illustrate--and close--the gap in access to new anti-tuberculosis drugs. Int J Tuberc Lung Dis. 2016 Feb; 20(2):145. PMID: 26792461.
    Citations: 1     Fields:    Translation:Humans
  83. Odone A, Calderon R, Becerra MC, Zhang Z, Contreras CC, Yataco R, Galea J, Lecca L, Bonds MH, Mitnick CD, Murray MB. Acquired and Transmitted Multidrug Resistant Tuberculosis: The Role of Social Determinants. PLoS One. 2016; 11(1):e0146642. PMID: 26765328.
    Citations: 14     Fields:    Translation:Humans
  84. Farhat MR, Jacobson KR, Franke MF, Kaur D, Sloutsky A, Mitnick CD, Murray M. Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2016 Mar; 54(3):727-33. PMID: 26763957; PMCID: PMC4767988.
    Citations: 27     Fields:    Translation:HumansCells
  85. Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, Keshavjee S, Koh WJ, Shiraishi Y, Viiklepp P, Yim JJ, Pasvol G, Robert J, Shim TS, Shin SS, Menzies D, Ahuja S, Ashkin D, Avendaño M, Banerjee R, Bauer M, Burgos M, Centis R, Cobelens F, Cox H, D'Ambrosio L, de Lange WCM, DeRiemer K, Enarson D, Falzon D, Flanagan K, Flood J, Gandhi N, Garcia-Garcia L, Granich RM, Hollm-Delgado MG, Holtz TH, Hopewell P, Iseman M, Jarlsberg LG, Kim HR, Lancaster J, Lange C, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Narita M, Nathanson E, Odendaal R, O'Riordan P, Pai M, Palmero D, Park SK, Pena J, Pérez-Guzmán C, Ponce-de-Leon A, Quelapio MID, Quy HT, Riekstina V, Royce S, Salim M, Schaaf HS, Seung KJ, Shah L, Shean K, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Sung SW, Tabarsi P, Tupasi TE, Vargas MH, van Altena R, van der Walt M, van der Werf TS, Westenhouse J, Yew WW. Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clin Infect Dis. 2016 Apr 01; 62(7):887-895. PMID: 26757804.
    Citations: 21     Fields:    Translation:Humans
  86. Cox HS, Furin JJ, Mitnick CD, Daniels C, Cox V, Goemaere E. The need to accelerate access to new drugs for multidrug-resistant tuberculosis. Bull World Health Organ. 2015 Jul 01; 93(7):491-7. PMID: 26170507; PMCID: PMC4490806.
    Citations: 3     Fields:    Translation:Humans
  87. Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB. Risk factors for and origins of COPD. Lancet. 2015 May 02; 385(9979):1723-1724. PMID: 25943930.
    Citations: 3     Fields:    Translation:Humans
  88. Franke MF, Becerra MC, Tierney DB, Rich ML, Bonilla C, Bayona J, McLaughlin MM, Mitnick CD. Counting pyrazinamide in regimens for multidrug-resistant tuberculosis. Ann Am Thorac Soc. 2015 May; 12(5):674-9. PMID: 25664920.
    Citations: 9     Fields:    Translation:HumansCells
  89. Harausz E, Cox H, Rich M, Mitnick CD, Zimetbaum P, Furin J. QTc prolongation and treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015 Apr; 19(4):385-91. PMID: 25859992.
    Citations: 12     Fields:    Translation:Humans
  90. Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB. Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis. 2015 Mar; 32:138-46. PMID: 25809770.
    Citations: 93     Fields:    Translation:Humans
  91. Lessem E, Cox H, Daniels C, Furin J, McKenna L, Mitnick CD, Mosidi T, Reed C, Seaworth B, Stillo J, Tisile P, von Delft D. Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives. Int J Infect Dis. 2015 Mar; 32:56-60. PMID: 25809757.
    Citations: 14     Fields:    Translation:Humans
  92. Farhat MR, Mitnick CD, Franke MF, Kaur D, Sloutsky A, Murray M, Jacobson KR. Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment. Int J Tuberc Lung Dis. 2015 Mar; 19(3):339-41. PMID: 25686144; PMCID: PMC4486051.
    Citations: 9     Fields:    Translation:HumansCells
  93. Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, Caoili J, Contreras C, Dalton T, Danilovits M, Demikhova OV, Ershova J, Gammino VM, Gelmanova I, Heilig CM, Jou R, Kazennyy B, Keshavjee S, Kim HJ, Kliiman K, Kvasnovsky C, Leimane V, Mitnick CD, Quelapio I, Riekstina V, Smith SE, Tupasi T, van der Walt M, Vasilyeva IA, Via LE, Viiklepp P, Volchenkov G, Walker AT, Wolfgang M, Yagui M, Zignol M. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med. 2015 Mar; 3(3):201-9. PMID: 25726085; PMCID: PMC4401426.
    Citations: 54     Fields:    Translation:HumansCells
  94. Tierney DB, Franke MF, Becerra MC, Alcántara Virú FA, Bonilla CA, Sánchez E, Guerra D, Muñoz M, Llaro K, Palacios E, Mestanza L, Hurtado RM, Furin JJ, Shin S, Mitnick CD. Time to culture conversion and regimen composition in multidrug-resistant tuberculosis treatment. PLoS One. 2014; 9(9):e108035. PMID: 25238411.
    Citations: 12     Fields:    Translation:Humans
  95. Velásquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, Shin SS, Andreev YG, Yanova G, Atwood SS, Mitnick CD, Franke MF, Rich ML, Keshavjee S. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis. 2014 Jul 01; 59(1):9-15. PMID: 24729493.
    Citations: 24     Fields:    Translation:HumansCells
  96. Parr JB, Mitnick CD, Atwood SS, Chalco K, Bayona J, Becerra MC. Concordance of resistance profiles in households of patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2014 Feb; 58(3):392-5. PMID: 24170196.
    Citations: 6     Fields:    Translation:HumansCells
  97. Brigden G, Nyang'wa BT, du Cros P, Varaine F, Hughes J, Rich M, Horsburgh CR, Mitnick CD, Nuermberger E, McIlleron H, Phillips PP, Balasegaram M. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ. 2014 Jan 01; 92(1):68-74. PMID: 24391302.
    Citations: 30     Fields:    Translation:HumansCells
  98. Anderson LF, Tamne S, Watson JP, Cohen T, Mitnick C, Brown T, Drobniewski F, Abubakar I. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Euro Surveill. 2013 Oct 03; 18(40). PMID: 24128699.
    Citations: 23     Fields:    Translation:HumansCells
  99. Seung KJ, Becerra MC, Atwood SS, Alcántara F, Bonilla CA, Mitnick CD. Salvage therapy for multidrug-resistant tuberculosis. Clin Microbiol Infect. 2014 May; 20(5):441-6. PMID: 23991934.
    Citations: 7     Fields:    Translation:HumansCells
  100. Palazuelos D, Ellis K, Im DD, Peckarsky M, Schwarz D, Farmer DB, Dhillon R, Johnson A, Orihuela C, Hackett J, Bazile J, Berman L, Ballard M, Panjabi R, Ternier R, Slavin S, Lee S, Selinsky S, Mitnick CD. 5-SPICE: the application of an original framework for community health worker program design, quality improvement and research agenda setting. Glob Health Action. 2013 Apr 03; 6:19658. PMID: 23561023.
    Citations: 24     Fields:    Translation:Humans
  101. Mitnick CD, Keravec J, Cohen T. Planning for the invisible: projecting resources needed to identify and treat all patients with MDR-TB. Int J Tuberc Lung Dis. 2013 Apr; 17(4):427-8. PMID: 23485374.
    Citations: 3     Fields:    Translation:Humans
  102. Mitnick CD, Franke MF, Rich ML, Alcantara Viru FA, Appleton SC, Atwood SS, Bayona JN, Bonilla CA, Chalco K, Fraser HS, Furin JJ, Guerra D, Hurtado RM, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Muñoz M, Palacios E, Sanchez E, Seung KJ, Shin SS, Sloutsky A, Tolman AW, Becerra MC. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS One. 2013; 8(3):e58664. PMID: 23516529.
    Citations: 30     Fields:    Translation:Humans
  103. Lu C, Liu Q, Sarma A, Fitzpatrick C, Falzon D, Mitnick CD. A systematic review of reported cost for smear and culture tests during multidrug-resistant tuberculosis treatment. PLoS One. 2013; 8(2):e56074. PMID: 23457502.
    Citations: 11     Fields:    Translation:HumansCells
  104. Becerra MC, Franke MF, Appleton SC, Joseph JK, Bayona J, Atwood SS, Mitnick CD. Tuberculosis in children exposed at home to multidrug-resistant tuberculosis. Pediatr Infect Dis J. 2013 Feb; 32(2):115-9. PMID: 22926210.
    Citations: 12     Fields:    Translation:HumansCellsPHPublic Health
  105. Franke MF, Appleton SC, Mitnick CD, Furin JJ, Bayona J, Chalco K, Shin S, Murray M, Becerra MC. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis. 2013 Mar; 56(6):770-6. PMID: 23223591.
    Citations: 26     Fields:    Translation:HumansCellsPHPublic Health
  106. Kurbatova EV, Gammino VM, Bayona J, Becerra MC, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012 Oct; 16(10):1335-43. PMID: 23107633.
    Citations: 31     Fields:    Translation:HumansCells
  107. Dooley KE, Mitnick C, Degroote MA, Obuku E, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N, Nuermberger E. Reply to Seddon, Schaaf, and Hesseling. Clin Infect Dis. 2013 Jan; 56(1):168-9. PMID: 22990846.
    Citations:    Fields:    Translation:HumansAnimals
  108. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Peña J, Pérez-Guzmán C, Quelapio MI, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, Van der Walt M, Van der Werf TS, Vargas MH, Viiklepp P, Westenhouse J, Yew WW, Yim JJ. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012; 9(8):e1001300. PMID: 22952439.
    Citations: 205     Fields:    Translation:Humans
  109. Dooley KE, Obuku EA, Durakovic N, Belitsky V, Mitnick C, Nuermberger EL. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis. 2013 May 01; 207(9):1352-8. PMID: 22807518; PMCID: PMC3693592.
    Citations: 30     Fields:    Translation:HumansAnimalsCells
  110. Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Viiklepp P, Zignol M, Cegielski JP. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb). 2012 Sep; 92(5):397-403. PMID: 22789497.
    Citations: 63     Fields:    Translation:Humans
  111. Daitch J, Frey ME, Silver D, Mitnick C, Daitch D, Pergolizzi J. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. Pain Physician. 2012 Jul; 15(3 Suppl):ES59-66. PMID: 22786462.
    Citations: 24     Fields:    Translation:Humans
  112. Loddenkemper R, Sotgiu G, Mitnick CD. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable? Eur Respir J. 2012 Jul; 40(1):9-11. PMID: 22753833.
    Citations: 9     Fields:    Translation:Humans
  113. Dooley KE, Mitnick CD, Ann DeGroote M, Obuku E, Belitsky V, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N, Nuermberger E. Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. Clin Infect Dis. 2012 Aug; 55(4):572-81. PMID: 22615332.
    Citations: 19     Fields:    Translation:HumansAnimals
  114. Alexy ER, Podewils LJ, Mitnick CD, Becerra MC, Laserson KF, Bonilla C. Concordance of programmatic and laboratory-based multidrug-resistant tuberculosis treatment outcomes in Peru. Int J Tuberc Lung Dis. 2012; 16(3):364-9. PMID: 22640451.
    Citations: 1     Fields:    Translation:HumansCells
  115. Furin J, Gegia M, Mitnick C, Rich M, Shin S, Becerra M, Drobac P, Farmer P, Hurtado R, Joseph JK, Keshavjee S, Kalandadze I. Eliminating the category II retreatment regimen from national tuberculosis programme guidelines: the Georgian experience. Bull World Health Organ. 2012 Jan 01; 90(1):63-6. PMID: 22271966.
    Citations: 13     Fields:    Translation:HumansPHPublic Health
  116. Kurbatova EV, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP. Frequency and type of microbiological monitoring of multidrug-resistant tuberculosis treatment. Int J Tuberc Lung Dis. 2011 Nov; 15(11):1553-5, i. PMID: 22008772.
    Citations: 6     Fields:    Translation:HumansCells
  117. Gammino VM, Taylor AB, Rich ML, Bayona J, Becerra MC, Bonilla C, Gelmanova I, Hollo V, Jaramillo E, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riektsina V, Tupasi TE, Wells CD, Zignol M, Cegielski PJ. Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects. Int J Tuberc Lung Dis. 2011 Oct; 15(10):1315-22. PMID: 22283887.
    Citations: 10     Fields:    Translation:HumansCells
  118. Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011 Sep; 38(3):516-28. PMID: 21828024.
    Citations: 297     Fields:    Translation:HumansCellsPHPublic Health
  119. Izu A, Cohen T, Mitnick C, Murray M, De Gruttola V. Bayesian methods for fitting mixture models that characterize branching tree processes: An application to development of resistant TB strains. Stat Med. 2011 Sep 30; 30(22):2708-20. PMID: 21717491.
    Citations: 1     Fields:    Translation:HumansCells
  120. Cox H, Ford N, Keshavjee S, McDermid C, von Schoen-Angerer T, Mitnick C, Goemaere E. Rational use of moxifloxacin for tuberculosis treatment. Lancet Infect Dis. 2011 Apr; 11(4):259-60. PMID: 21453864.
    Citations: 5     Fields:    Translation:HumansCells
  121. Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, Bayona J, Murray M, Atwood SS, Mitnick CD. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet. 2011 Jan 08; 377(9760):147-52. PMID: 21145581.
    Citations: 57     Fields:    Translation:HumansCellsPHPublic Health
  122. Mitnick C, Horsburgh CR. Encouraging news for multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med. 2010 Dec 01; 182(11):1337-8. PMID: 21123746.
    Citations: 3     Fields:    Translation:Humans
  123. Stryjewski TP, Benadretti DB, Zhao SD, Rowe S, Mitnick CD. Preliminary clinical outcomes from the Peruvian National Cataract Elimination Plan. Rev Panam Salud Publica. 2010 Oct; 28(4):282-8. PMID: 21152716.
    Citations:    Fields:    Translation:Humans
  124. Becerra MC, Appleton SC, Franke MF, Chalco K, Bayona J, Murray MB, Mitnick CD. Recurrence after treatment for pulmonary multidrug-resistant tuberculosis. Clin Infect Dis. 2010 Sep 15; 51(6):709-11. PMID: 20687835.
    Citations: 12     Fields:    Translation:Humans
  125. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2010 Jul 01; 51(1):6-14. PMID: 20504231.
    Citations: 93     Fields:    Translation:HumansCells
  126. Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother. 2009 Feb; 10(3):381-401. PMID: 19191677.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  127. Mitnick CD, Appleton SC, Shin SS. Epidemiology and treatment of multidrug resistant tuberculosis. Semin Respir Crit Care Med. 2008 Oct; 29(5):499-524. PMID: 18810684.
    Citations: 14     Fields:    Translation:Humans
  128. Bonilla CA, Crossa A, Jave HO, Mitnick CD, Jamanca RB, Herrera C, Asencios L, Mendoza A, Bayona J, Zignol M, Jaramillo E. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One. 2008 Aug 13; 3(8):e2957. PMID: 18698423.
    Citations: 24     Fields:    Translation:Humans
  129. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, Fitzmaurice GM, Alcantara Viru FA, Appleton SC, Bayona JN, Bonilla CA, Chalco K, Choi S, Franke MF, Fraser HS, Guerra D, Hurtado RM, Jazayeri D, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Muñoz M, Palacios E, Sanchez E, Sloutsky A, Becerra MC. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008 Aug 07; 359(6):563-74. PMID: 18687637; PMCID: PMC2673722.
    Citations: 113     Fields:    Translation:HumansCells
  130. Cobelens FG, Heldal E, Kimerling ME, Mitnick CD, Podewils LJ, Ramachandran R, Rieder HL, Weyer K, Zignol M. Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med. 2008 Jul 08; 5(7):e150. PMID: 18613746.
    Citations: 18     Fields:    Translation:Humans
  131. Franke MF, Appleton SC, Bayona J, Arteaga F, Palacios E, Llaro K, Shin SS, Becerra MC, Murray MB, Mitnick CD. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis. 2008 Jun 15; 46(12):1844-51. PMID: 18462099.
    Citations: 68     Fields:    Translation:HumansCells
  132. Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med. 2007 Nov 06; 4(11):e292. PMID: 17988168.
    Citations: 21     Fields:    Translation:HumansCells
  133. Nardell EA, Mitnick CD. Are second-line drugs necessary to control multidrug-resistant tuberculosis? J Infect Dis. 2006 Nov 01; 194(9):1194-6. PMID: 17041843.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  134. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, Gupta R, Bayona J, Blöndal K, Caminero JA, Cegielski JP, Danilovits M, Espinal MA, Hollo V, Jaramillo E, Leimane V, Mitnick CD, Mukherjee JS, Nunn P, Pasechnikov A, Tupasi T, Wells C, Raviglione MC. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis. 2006 Sep; 12(9):1389-97. PMID: 17073088; PMCID: PMC3294733.
    Citations: 61     Fields:    Translation:HumansPHPublic Health
  135. Drobac PC, Mukherjee JS, Joseph JK, Mitnick C, Furin JJ, del Castillo H, Shin SS, Becerra MC. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics. 2006 Jun; 117(6):2022-9. PMID: 16740844.
    Citations: 28     Fields:    Translation:Humans
  136. Shin SS, Furin JJ, Alcántara F, Bayona J, Sánchez E, Mitnick CD. Long-term follow-up for multidrug-resistant tuberculosis. Emerg Infect Dis. 2006 Apr; 12(4):687-8. PMID: 16704823; PMCID: PMC3294679.
    Citations: 9     Fields:    Translation:HumansCells
  137. Rich ML, Socci AR, Mitnick CD, Nardell EA, Becerra MC, Bonilla C, Bayona J, Seung KJ, Furin J, Farmer PE, Mukherjee JS. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. Int J Tuberc Lung Dis. 2006 Mar; 10(3):290-6. PMID: 16562709.
    Citations: 6     Fields:    Translation:Humans
  138. Heldal E, Gammino V, Hollo V, Laserson K, Mitnick C, Rich M, Trebucq A. Category IV recording and reporting system. Stop TB Department, World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuerculosis. 2006; 114-123.
  139. Heldal E, Gammino V, Hollo V, Laserson K, Mitnick C, Rich M, Trebucq A. Definitions: case registration, bacteriology and treatment outcomes. Stop TB Department, World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. 2006; 18-23.
  140. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, Zarovska E, Rich ML, Fraser HS, Alarcón E, Cegielski JP, Grzemska M, Gupta R, Espinal M. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005 Jun; 9(6):640-5. PMID: 15971391.
    Citations: 128     Fields:    Translation:Humans
  141. Mitnick, CD. Operational Research in Tuberculosis. 2005.
  142. Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis. 2004 Mar; 8(3):361-8. PMID: 15139476.
    Citations: 27     Fields:    Translation:Humans
  143. Chavez Pachas AM, Blank R, Smith Fawzi MC, Bayona J, Becerra MC, Mitnick CD. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis. 2004 Jan; 8(1):52-8. PMID: 14974746.
    Citations: 18     Fields:    Translation:HumansCells
  144. Choi SS, Jazayeri DG, Mitnick CD, Chalco K, Bayona J, Fraser HS. Implementation and initial evaluation of a Web-based nurse order entry system for multidrug-resistant tuberculosis patients in Peru. Stud Health Technol Inform. 2004; 107(Pt 1):202-6. PMID: 15360803.
    Citations: 9     Fields:    Translation:Humans
  145. Shin SS, Hyson AM, Castañeda C, Sánchez E, Alcántara F, Mitnick CD, Fawzi MC, Bayona J, Farmer PE, Kim JY, Furin JJ. Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2003 Apr; 7(4):347-53. PMID: 12729340.
    Citations: 11     Fields:    Translation:Humans
  146. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, Sánchez E, Sarria M, Becerra M, Fawzi MC, Kapiga S, Neuberg D, Maguire JH, Kim JY, Farmer P. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003 Jan 09; 348(2):119-28. PMID: 12519922.
    Citations: 158     Fields:    Translation:Humans
  147. Partners In Health. The PIH Guide to the Medical Management of Multidrug-Resistant Tuberculosis. 2003.
  148. Fraser HS, Jazayeri D, Mitnick CD, Mukherjee JS, Bayona J. Informatics tools to monitor progress and outcomes of patients with drug resistant tuberculosis in Peru. Proc AMIA Symp. 2002; 270-4. PMID: 12463829.
    Citations: 23     Fields:    Translation:HumansCells
  149. Partners In Health/Program in Infectious Disease and Social Change. A Dots-Plus Handbook: Guide to the Community-Based Treatment of MDR-TB. 2002.
  150. Kim JY, Mitnick CD, Bayona J, Blank R, Nardell E, Mukherjee JS, Rich ML, Farmer PE, Becerra MC, Murray M. Examing assumptions about multidrug-resistant TB control. Bulletin of the World Health Organization. 2002; 80(6):498-9.
  151. Program in Infectious Disease and Social Change in consultation with Stop TB Department, World Health Organization. Statement on the Role of the Corporate Sector in Global Tuberculosis Control. 2002.
  152. Fraser HS, Jazayeri D, Mitnick CD, Mukherjee JS, Bayona J. Informatics tools to monitor progress and outcomes of patients with drug resistant tuberculosis in Peru. Proceedings of AMIA Symposium. 2002; 270-4.
  153. Furin JJ, Mitnick CD, Shin SS, Bayona J, Becerra MC, Singler JM, Alcantara F, Castañieda C, Sanchez E, Acha J, Farmer PE, Kim JY. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001 Jul; 5(7):648-55. PMID: 11467371.
    Citations: 46     Fields:    Translation:Humans
  154. Widmer S, Mitnick C, editors. Review of Tuberculosis Control Programs in Eastern and Central Europe and the Former Soviet Union. 2001.
  155. Mitnick, CD. Outcomes of Directly Observed, Individualized Community-Based Therapy for Multidrug-Resistant Tuberculosis in a Shantytown in Northern Lima, Peru. 2001.
  156. Farmer PE, Kim JY, Mitnick CD, Timperi R. Responding to outbreaks of MDR-TB: introducing DOTS-plus. Reichman LB, Hershfield ES, eds. Tuberculosis: A Comprehensive International Approach. 2000; 447-69.
  157. Mitnick, CD. Poverty, Culture and Infectious Diseases. 2000.
  158. Mitnick, CD. Health of Prisoners. 1999.
  159. Farmer P, Furin J, Bayona J, Becerra M, Henry C, Hiatt H, Kim JY, Mitnick C, Nardell E, Shin S. Management of MDR-TB in resource-poor countries. Int J Tuberc Lung Dis. 1999 Aug; 3(8):643-5. PMID: 10460095.
    Citations: 4     Fields:    Translation:Humans
  160. Mitnick CD, Farmer PE. . Promise and peril: TB and multidrug-resistant tuberculosis in Azerbaijan. Farmer PE, Becerra M, Kim JY, eds. The Global Impact of Drug-Resistant Tuberculosis. 1999; 87-105..
  161. Farmer PE, Bayona J, Becerra M, Furin J, Henry C, Hiatt H, Kim JY, Mitnick C, Nardell E, Shin S. DOTS plus strategy in resource-poor countries. International Journal of Tuberculosis and Lung Disease. 1999; 3(9):844.
  162. Farmer P, Bayona J, Becerra M, Furin J, Henry C, Hiatt H, Kim JY, Mitnick C, Nardell E, Shin S. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis. 1998 Nov; 2(11):869-76. PMID: 9848606.
    Citations: 33     Fields:    Translation:Humans
  163. Mitnick C, Furin J, Henry C, Ross J. Tuberculosis among the foreign born in Massachusetts, 1982-1994: a reflection of social and economic disadvantage [The Eddie O'Brien Lecture]. Int J Tuberc Lung Dis. 1998 Sep 01; 2(9):32-40. PMID: 29343325.
    Citations:    
  164. Mitnick C, Furin J, Henry C, Ross J. Tuberculosis among the foreign born in Massachusetts, 1982-1994: a reflection of social and economic disadvantage. Int J Tuberc Lung Dis. 1998 Sep; 2(9 Suppl 1):S32-40. PMID: 9755963.
    Citations: 1     Fields:    Translation:Humans
  165. Partners In Health. Normes et procedures du traitement de la tuberculose. Clinique Bon Sauveur, Zanmi Lasante. 1998.
  166. Fawzi MC, Jean-Baptiste M, Rosenthal B, Mitnick C. Health impact of human rights violations in Haitian refugees. Lancet. 1997 Aug 02; 350(9074):371-2. PMID: 9251672.
    Citations: 2     Fields:    Translation:Humans
  167. Farmer P, Bayona J, Becerra M, Daily J, Furin J, Garcia D, Henry C, Kim J, Mitnick C, Nardell E, Raymonville M, Shin S, Small P. Poverty, inequality and drug resistance: meeting community needs. Proceedings of the International Union Against Tuberculosis and Lung Disease. 1997; 88-102.
  168. Mitnick, CD. Consumption of the Poor: Tuberculosis in the 20th Century. 1996.
  169. Mitnick, CD. Evaluation and Monitoring of Public Health Interventions in Developing Countries. 1995.
  170. Holmes A, Barnett E, Mitnick C, Phillips S, Gas M, Wais M, Wilson M. . The development of an appropriate screening and treatment strategy for schistosomiasis in the Somalian refugee population followed at Boston City Hospital's International Clinic. Proceedings of the Infectious Disease Society of America, 33rd Meeting. 1995.
  171. Mitnick, C. Epidemiology of Infectious Diseases of Importance in Developing Countries. 1994.
  172. Wilson A, Michaels B, Mitnick C, editors. Malaria and Development in Sub-Saharan Africa. 1991.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Mitnick's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (287)
Explore
_
Co-Authors (50)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.